URGENT ALERT: Please beware of fraudulent Telegram and Whatsapp groups pretending to be affiliated with Sygnia and Sygnia staff members. Do not engage with these malicious and fraudulent groups in any way. Please direct all queries to admin@sfs.sygnia.co.za.

Sygnia Itrix Solactive Healthcare 150 ETF

GLOBAL – EQUITY – GENERAL

The objective of the Sygnia Itrix Solactive Healthcare 150 ETF is to provide an investment vehicle that gives easy access to investors who want to achieve long term capital appreciation in tracking the performance of the Solactive Developed Markets Healthcare 150 Index (.SDMH150P) (“benchmark index”).

“Our funds are designed to challenge the status quo, because we want our investors to feel like the world is their oyster, that everything is possible.”

Kyle Hulett, Head of Investments

About the Fund

Investment objective and strategy
The objective of the Sygnia Itrix Solactive Healthcare 150 ETF is to provide an investment vehicle that gives easy access to investors who want to achieve long term capital appreciation in tracking the performance of the Solactive Developed Markets Healthcare 150 Index (.SDMH150P) (“benchmark index”). The Sygnia Itrix Solactive Healthcare 150 ETF is a high risk, passively managed index tracking fund, registered as a Collective Investments Scheme, and is listed on the Johannesburg Stock Exchange as an Exchange Traded Fund with the objective is to replicate the price and yield performance of the Solactive Developed Markets Healthcare 150 Index as closely as possible by physically holding a portfolio of securities equivalent to the basket of securities comprising the Index and in similar weightings to that of the Index. The Solactive Developed Markets Healthcare 150 Index tracks the performance of the largest 150 companies from the developed market Healthcare Industry and is based on the Solactive Global Benchmark Series. Constituents are selected and weighted based on free-float market capitalisation. Index Performance data can be sourced from Solactive, Reuters and at www.sygnia.co.za.

What the fund invests in

Top 10 Holdings as at September 2023PercentageAllocation
UnitedHealth Group Ord Shs 6.6
Eli Lilly Ord Shs6.4
Johnson & Johnson Ord Shs 5.7
Novo Nordisk Ord Shs Class B 4.1
AbbVie Ord Shs 3.7
Merck & Co Ord Shs 3.7
Astrazeneca Ord Shs 2.8
Novartis Ord Shs 2.8
Thermo Fisher Scientific Ord Shs 2.7
Roche Holding Par Shs 2.7

Risk profile
The Fund has a 100% strategic allocation to global equities. The risk in the Fund is managed by spreading investments across countries and individual shares. However, the structure of the Fund is dictated by the composition of the Solactive Developed Markets Healthcare 150 Index. The focus on the largest, more liquid companies provides an added benefit in terms of risk management.

For the investor

Who Should Invest?
The Sygnia Itrix Solactive Healthcare 150 ETF has a high risk profile and is designed to track the Index as closely as possible by buying securities included in the Index at similar weighting as they are included in the Index. It is a suitable investment for investors seeking higher returns, those who are willing to tolerate higher volatility and investors who aim to maximise capital accumulation over a longer-term time horizon. The investment is also suitable for investors who wish to maximise their returns in the most cost-effective manner without the need to select asset managers or take on the risk of active and subjective investment decision making processes.

Fees

Annual Management Fee 0.44% p.a. (excl. VAT)
Other Expenses0.01%
VAT0.07%
Total Expense Ratio (TER)0.51% (Dec 2023)
Transaction Costs (TC)0.01% (Dec 2023)
Total Investment Charge (TIC)0.53% (Dec 2023)

A higher TER does not necessarily imply a poor return, nor does a low TER imply a good return. The current TER may not necessarily be an accurate indication of future TER’s. Transaction Costs are a necessary cost in administering the Financial Product and impacts Financial Product returns. It should not be considered in isolation as returns may be impacted by many other factors over time including market returns, the type of Financial Product, the investment decisions of the investment manager and the TER.

Disclosures

Disclosure
The Sygnia Group is a member of the Association for Savings and Investment SA. Sygnia ltrix (RF) (Pty) Ltd is a registered and approved Manager under the Collective Investment Schemes Control Act, 2002. Sygnia Asset Management (Pty) Limited (FSP 873), an authorised financial services provider, is the appointed investment manager of the Fund. Sygnia ltrix does not provide any guarantee with respect to the capital or return of the portfolio. Collective Investment Schemes (CIS) are generally medium to long-term investments. Collective investment schemes are traded at ruling prices and can engage in borrowing and scrip lending. The value of investments/units may go down as well as up and past performance is not necessarily an indicator of future performance. ETFs trade on stock exchanges and may therefore incur additional costs associated with listed securities. Unlike a unit trust, which can be bought or sold only once per day, an ETF can be traded intraday, during exchange trading hours. ETFs may invest in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, liquidity, and foreign exchange risks. Performance is calculated for the portfolio, and the individual investor performance may differ as a result of trading cost, price paid for investment share. Additional information on the Index including its performance and tracking error can be viewed on the relevant Minimum Disclosure Document (MDD) on www.sygnia.co.za. A schedule of fees, charges and where the ETF engages in securities lending activities, information on such securities lending activities may be requested via admin@sfs.sygnia.co.za or 0860 794 642. The complete terms and conditions of your ETF investment are contained in the fund's offering circular, pre-listing statement, programme memorandum and/or supplemental deed and index constituents with prices are published daily on Sygnia's website. The documents/information may be obtained from www.sygnia.co.za or on request from Sygnia. Nothing in this document shall be considered to state or imply that the Fund is suitable for a particular type of investor. All the portfolio options presented are approved collective investment schemes in terms of the Collective Investment Schemes Control Act, No 45 of 2002 ("CISCA"). The Manager has the right to close any portfolios to new investors to manage them more efficiently in accordance with their mandates. A copy of the Minimum Disclosure Document (MDD) is available on our website: www.sygnia.co.za.

Index Disclosure
The funds or securities referred to herein are not sponsored, endorsed or promoted by MSCI, and MSCI bears no liability with respect to any such funds or securities or any index on which such funds or securities are based. The complete terms and conditions of your ETF investment are contained in the fund’s Offering Circular and Pre-Listing Statement and the relevant Supplement.

Fund overview

Risk profile
High
Time horizon
5+ years
Fund launch date06-08-2021Fund sizeR 673 millionBenchmarkSolactive Developed Markets Healthcare 150 Index

Portfolio managers

Sygnia Asset Management (Pty) Ltd

Need help? We are here.

Call us today

Call us on 0860 794 642
Monday - Friday, 8am - 5pm.

Call now


Send us a message

Contact our support centre and we’ll get back to you as soon as possible. During business hours, we generally respond within 48 hours.

Email us